Since nintedanib showed clinical efficacy for both SSc (a disease partly driven by IL-6 signaling) [33,34] and IPF [4], similar effects may be expected from tocilizumab treatment in IPF, but clinical studies are necessary to confirm this hypothesis. This evidence concerns the gene IL6 and idiopathic interstitial pneumonia.